(Q33576223)

28 July 2017

1 reference

title

Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism (English)

1 reference

cost-effectiveness analysis

28 July 2017

0 references

1 reference

1 reference

1 reference

ORCID Public Data File 2021

author name string

Anderson DR

series ordinal

1

1 reference

28 July 2017

O'Brien BJ

series ordinal

2

1 reference

28 July 2017

publication date

1 July 1997

1 reference

28 July 2017

1 reference

28 July 2017

volume

12

1 reference

28 July 2017

issue

1

1 reference

28 July 2017

page(s)

17-29

1 reference

Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery

28 July 2017

cites work

1 reference

12 December 2020

Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis

1 reference

12 December 2020

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

1 reference

12 December 2020

RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group

1 reference

12 December 2020

A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation

1 reference

12 December 2020

Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery. A meta-analysis.

1 reference

12 December 2020

Cost-effectiveness of venous thromboembolism prophylaxis in surgery

1 reference

12 December 2020

The cost-effectiveness of prevention of post-operative thromboembolism.

1 reference

12 December 2020

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

12 December 2020

An evaluation of impedance plethysmography and 125I-fibrinogen leg scanning in patients following hip surgery.

1 reference

12 December 2020

Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism

1 reference

12 December 2020

Prevention of venous thromboembolism

1 reference

12 December 2020

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

1 reference

12 December 2020

Perioperative thrombosis prophylaxis with low molecular weight heparins in elective hip surgery. Clinical and economic considerations

1 reference

12 December 2020

Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group

1 reference

12 December 2020

Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.

1 reference

12 December 2020

Prophylaxis of venous thromboembolism: analysis of cost effectiveness

1 reference

12 December 2020

Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery

1 reference

12 December 2020

Antithrombotic therapy for venous thromboembolic disease

1 reference

12 December 2020

Heparin and the in-hospital management of deep venous thrombosis: cost considerations

1 reference

12 December 2020

Clinical recommendations using levels of evidence for antithrombotic agents

1 reference

12 December 2020

Lower extremity venography with iohexol: results and complications

1 reference

12 December 2020

Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?

1 reference

12 December 2020

Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty

1 reference

12 December 2020

Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis

1 reference

12 December 2020

Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis

1 reference

12 December 2020

Cost-effectiveness of prophylaxis in total hip replacement

1 reference

12 December 2020

Cost-benefit analysis of prophylaxis against deep vein thrombosis in surgery

1 reference

12 December 2020

Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients

1 reference

12 December 2020

Epidemiology and natural history of venous thromboembolism

1 reference

12 December 2020

Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement

1 reference

12 December 2020

The economics of general thromboembolic prophylaxis

1 reference

12 December 2020

Two strategies for prophylaxis of fatal postoperative pulmonary embolism. Cost-effectiveness analysis

1 reference

12 December 2020

A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.

1 reference

12 December 2020

A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery

1 reference

12 December 2020

Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis

1 reference

12 December 2020

Cost/benefit aspects on thromboprophylaxis

1 reference

12 December 2020

10.2165/00019053-199712010-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1030013553

0 references

1 reference